Canada markets close in 2 hours 59 minutes

Organigram Holdings Inc. (OGI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.8912+0.0015 (+0.17%)
As of 01:01PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.8897
Bid0.8962 x 2200
Ask0.8994 x 900
Day's Range0.8830 - 0.9098
52 Week Range0.7000 - 1.8700
Avg. Volume1,314,465
Market Cap283.563M
Beta (5Y Monthly)1.37
PE Ratio (TTM)N/A
EPS (TTM)-0.0910
Earnings DateApr 10, 2023 - Apr 14, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.13
  • Business Wire

    Organigram Provides NASDAQ Listing Update

    TORONTO, January 26, 2023--Organigram Holdings Inc. ("Organigram" or the "Company") (TSX: OGI; NASDAQ: OGI), today announced that it received notification (the "Notification") from The Nasdaq Stock Market LLC ("NASDAQ") that it is not in compliance with the minimum bid price requirement in NASDAQ Listing Rule 5450(a)(1) for continued listing on the NASDAQ Global Select Market, since the closing bid price for the Company’s common shares listed on NASDAQ was below US$1.00 for 30 consecutive tradin

  • Motley Fool

    3 Cannabis Stocks to Buy and Hold for the Next 10 Years

    It can be hard for investors to see anything good in the cannabis space through all the smoke of 2022's collapsing share prices. Thanks to the market's general malaise regarding the industry, at least three are selling at discounts and look likely to be great long-term holdings over the next decade: Trulieve Cannabis (OTC: TCNNF), NewLake Capital Partners (OTC: NLCP) and OrganiGram Holdings (NASDAQ: OGI). All three cannabis companies are trading at price-to-book ratios below what their assets would bring if sold off, and at lower ratios than other large cannabis companies such as Canopy Growth and Curaleaf Holdings.

  • Zacks

    OrganiGram (OGI) Reports Q1 Loss, Misses Revenue Estimates

    OrganiGram (OGI) delivered earnings and revenue surprises of 0% and 1.43%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?